Cargando…

The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection

The ubiquitous distribution of vitamin D receptors in the human body is responsible for the pleiotropic effects of vitamin D-receptor activation. We discuss the possible beneficial effects of a selective activator of vitamin D receptor, paricalcitol, on the cardiovascular system in chronic heart fai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duplancic, Darko, Cesarik, Marijan, Poljak, Nikola Kolja, Radman, Maja, Kovacic, Vedran, Radic, Josipa, Rogosic, Veljko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573827/ https://www.ncbi.nlm.nih.gov/pubmed/23430986 http://dx.doi.org/10.2147/CIA.S38349

Ejemplares similares

Vitamin D Supplementation and Clinical Outcomes in Severe COVID-19 Patients—Randomized Controlled Trial
por: Domazet Bugarin, Josipa, et al.
Publicado: (2023)

Effects of Paricalcitol on Body Composition in Vitamin D-Deficient Rats
por: Koohpeyma, Farhad, et al.
Publicado: (2021)

Simple and Rapid Method for the Determination of Uric Acid-Independent Antioxidant Capacity
por: Duplancic, Darko, et al.
Publicado: (2011)

Effects of Vitamin D(3) and Paricalcitol on Immature Cardiomyocytes: A Novel Role for Vitamin D Analogs in the Prevention of Cardiovascular Diseases
por: Pacini, Stefania, et al.
Publicado: (2013)

Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis
por: Stavenuiter, Andrea W. D., et al.
Publicado: (2015)

Nutritional Status and Indicators of 2-Year Mortality and Re-Hospitalizations: Experience from the Internal Clinic Departments in Tertiary Hospital in Croatia
por: Miličević, Tanja, et al.
Publicado: (2020)

Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol
por: Mimura, Luiza Ayumi Nishiyama, et al.
Publicado: (2021)

The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control
por: Cozzolino, Mario, et al.
Publicado: (2011)

Cardiorenal Protection in Diabetic Kidney Disease
por: Lee, Jason F., et al.
Publicado: (2021)

Cardiovascular and Renal Links along the Cardiorenal Continuum
por: García-Donaire, José A., et al.
Publicado: (2011)

Barotrauma in patients with severe coronavirus disease 2019—retrospective observational study
por: Bajto, Petra, et al.
Publicado: (2023)

Cardiorenal benefits of finerenone: protecting kidney and heart
por: González-Juanatey, José R., et al.
Publicado: (2023)

Antiapoptotic Effect of Paricalcitol in Gentamicin-induced Kidney Injury
por: Suh, Sang Heon, et al.
Publicado: (2013)

Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients
por: Izquierdo, María Jesús, et al.
Publicado: (2012)

Effects of Different Inhalation Therapy on Ventilator-Associated Pneumonia in Ventilated COVID-19 Patients: A Randomized Controlled Trial
por: Delić, Nikola, et al.
Publicado: (2022)

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
por: Koufakis, Theocharis, et al.
Publicado: (2021)

A Foreign Body (Toothbrush) in the Esophagus of a Patient with Hiatal Hernia
por: Klancnik, Marisa, et al.
Publicado: (2017)

Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2013)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease
por: Lucisano, Silvia, et al.
Publicado: (2015)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
por: Arenas Jimenez, María Dolores, et al.
Publicado: (2021)

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation
por: D’Marco, Luis, et al.
Publicado: (2022)

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
por: Hou, Yi-Chou, et al.
Publicado: (2020)

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
por: Salvatore, Teresa, et al.
Publicado: (2022)

Vitamin D and Sjögren’s Disease: Revealing the Connections—A Systematic Review and Meta-Analysis
por: Radić, Mislav, et al.
Publicado: (2023)

Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease()
por: Darabian, Sirous, et al.
Publicado: (2012)

Mitochondrial Dysfunction in Cardiorenal Syndrome 3: Renocardiac Effect of Vitamin C
por: Neres-Santos, Raquel Silva, et al.
Publicado: (2021)

FLOW CHANGES IN ORBITAL VESSELS DETECTED WITH COLOR DOPPLER ULTRASOUND IN PATIENTS WITH EARLY DYSTHYROID OPTIC NEUROPATHY
por: Lešin, Mladen, et al.
Publicado: (2018)

Brachial flow—mediated dilation and carotid intima—media thickness in glaucoma patients
por: Bojic, Lovro, et al.
Publicado: (2022)

The Cardiorenal Syndrome
por: Rosner, Mitchell H., et al.
Publicado: (2011)

Cardiorenal syndrome
por: Schetz, Miet
Publicado: (2009)

Cardiorenal syndrome
por: Ye, Wen Qing Wendy, et al.
Publicado: (2023)

Acute Childhood Cardiorenal Syndrome and Impact of Cardiovascular Morbidity on Survival
por: Olowu, Wasiu A.
Publicado: (2011)

Erratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2014)

Vitamin D Analogues and Coronary Calcification in CKD Stages 3 and 4: A Randomized Controlled Trial of Calcitriol Versus Paricalcitol
por: Anis, Karim H., et al.
Publicado: (2020)

The Event-related Potential P300 in Patients with Migraine
por: Titlic, Marina, et al.
Publicado: (2015)

Chondro/Osteoblastic and Cardiovascular Gene Modulation in Human Artery Smooth Muscle Cells That Calcify in the Presence of Phosphate and Calcitriol or Paricalcitol
por: Shalhoub, V, et al.
Publicado: (2010)

Comparison of the Pharmacological Effects of Paricalcitol and Doxercalciferol on the Factors Involved in Mineral Homeostasis
por: Wu-Wong, J. Ruth, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_n3rhtfoqcl1mgf54dvt37ld7cp